We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing global threat posed by AMR
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has today lauded the conclusions of a NHS England and the National Institute for Health and Care Excellence (NICE)…
Latest News
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
“The announcement today that the government is increasing public R&D investment to record…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Infex Therapeutics is pressing ahead with a major development of its pandemic resilience…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and…